KURA Kura Oncology
- 20.280
- +0.660+3.36%
Kura Oncology News
Sector Update: Health Care Stocks Advance Premarket Monday
Health care stocks were advancing premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.5% and the iShares Biotechnology ETF (IBB) was 0.8% higher recently. Vaxxinity (VAXX) was r
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation
Kura Oncology (KURA) said Monday the US Food and Drug Administration has granted Breakthrough Therapy Designation for its potential leukemia drug ziftomenib.
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Kura Oncology said Monday it received a breakthrough therapy designation from regulators for ziftomenib, its potential treatment for a form of leukemia.
Express News | Kura Oncology Shares Are Trading Higher After the Company Received FDA Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Kura Oncology's Ziftomenib, Has Been Granted FDA Breakthrough Therapy Designation For Relapsed/Refractory NPM1-mutant Acute Myeloid Leukemia
Express News | Kura Oncology Inc - Registration-Directed Trial of Ziftomenib in Npm1-Mutant Aml on Track to Complete Enrollment by Mid-2024
Express News | Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in Npm1-Mutant Aml
MGNX, SBNY and SLP Are Among After Hour Movers
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price target.
Express News | Kura Oncology Shares Are Trading Higher After the Company Announced That It Dosed Its First Patient in Its Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Buy Rating Affirmed: Kura Oncology's KO-2806 Shows Promising Clinical and Market Potential
Express News | Kura Oncology Reports First Patient Dosed In Trial Of KO-2806 Plus Cabozantinib In Renal Cell Carcinoma
Buy Rating for Kura Oncology Amid Strong Q4 Results and Promising Ziftomenib Trials
Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Kura Oncology Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), UniQure (QURE)
Express News | Wedbush Reiterates Outperform on Kura Oncology, Maintains $37 Price Target
Kura Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/28/2024 70.04% Wedbush → $37 Reiterates Outperform → Outperform 01/31/2024 47.06% JMP Securities $22 →
Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)
Strong Buy Rating for Kura Oncology Based on Solid Financials and Promising Clinical Trials
Analysis
Price Target
No Data
